Immunogenicity of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hemodialysis Patients: A Case-Control Study
Abstract
Background/objectives: Studies have shown that immune responses to COVID-19 vaccines are impaired in dialysis patients which may affect immunity to vaccines. Therefore, this study aimed to evaluate SARS-COV-2 neutralizing antibodies in hemodialysis patients for 2 and 6 weeks after receiving inactivated Sinopharm vaccine.
Methods: In this study, 172 people were divided into two groups. The first group included 108 hemodialysis patients, while the second group included 64 health workers as a control group. In order to evaluate SARS-COV-2 neutralizing antibodies titers, the peripheral blood samples were collected from all participants 2 and 6 weeks after receiving the second dose of Sinopharm vaccine. Samples were centrifuged and the neutralizing antibody against receptor-binding domain (RBD) was determined using the indirect ELISA technique.
Results: Hemodialysis patients had lower titers of IgG neutralizing antibodies compared to the control group (P <0.001). The titers of SARS-COV-2 neutralizing antibodies were not significantly different at 2 weeks in comparison with 6 weeks after vaccination (P=0.9204). Our findings showed a significant increase in titers of IgG neutralizing antibodies after vaccination in people with a history of COVID-19 (P=0.002). The seropositivity rate for neutralizing antibodies against RBD was significantly different between seropositive (immune) and seronegative (non-immune) patients 6 weeks after vaccination (P=0.022).
Conclusions: The titers of neutralizing antibodies against SARS-COV-2 were lower in hemodialysis patients than in healthy individuals. This is probably due to the poor immune system. However, patients who received two doses of inactivated Sinopharm vaccine showed a higher antibody titer 6 weeks after vaccination.
2. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145-151
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-513
4. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762-768
5. Chung EYM, Palmer SC, Natale P, et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis 2021;78(6):804-815
6. Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020;35(11):1973-1983
7. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. Am J Kidney Dis 2021;77(5):748-756.e741
8. Kikuchi K, Nangaku M, Ryuzaki M, et al. COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures. Ther Apher Dial 2020;24(4):361-365
9. Yen JS, Wang IK, Yen TH. COVID-19 vaccination and dialysis patients: why the variable response. Qjm 2021;114(7):440-444
10. Forni G, Mantovani AJCD, Differentiation. COVID-19 vaccines: where we stand and challenges ahead. 2021;28(2):626-639
11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. 2020
12. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99-111
13. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. 2021;397(10275):671-681
14. Beijing Institute of Biological Products Co. L. Recommendation for an Emergency Use Listing of COVID-19 Vaccine BIBP. https://extranet.who.int/pqweb/file/4960602/download.
15. Wang H, Zhang Y, Huang B, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell 2020;182(3):713-721.e719
16. Gharate JS, Daitkar SA, Aher KA. Approved COVID 19 Vaccines: a Review. World Journal of Pharmaceutical Research 2021;10(10):523-542
17. Neutralizing antibody. https://www.biologyonline.com/dictionary/Neutralizing_antibody.
18. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021
19. Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020;586(7830):583-588
20. Güzel E, Çelikkol A, Erdal B, et al. Immunogenicity after CoronaVac vaccination. Rev Assoc Med Bras (1992) 2021;67(10):1403-1408
21. Erol Ç, Yanık Yalçın T, Sarı N, et al. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients. Exp Clin Transplant 2021;19(12):1334-1340
22. Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science (New York, N.Y.) 2020;369(6506):956-963
23. Torreggiani M, Blanchi S, Fois A, et al. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney international 2021;99(6):1494-1496
24. Windpessl M, Bruchfeld A, Anders HJ, et al. COVID-19 vaccines and kidney disease. Nat Rev Nephrol 2021;17(5):291-293
25. Agur T, Ben-Dor N, Goldman S, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. Nephrol Dial Transplant 2021
26. Stumpf J, Siepmann T, Lindner T, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur 2021;9:100178
27. Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv Chronic Kidney Dis 2019;26(1):8-15
28. Frantzen L, Cavaille G, Thibeaut S, et al. Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort. Nephrol Dial Transplant 2021
29. Grupper A, Sharon N, Finn T, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol 2021;16(7):1037-1042
30. Jahn M, Korth J, Dorsch O, et al. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Vaccines (Basel) 2021;9(4)
31. Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant 2021;36(9):1709-1716
32. Chen Y, Yin S, Tong X, et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clinical Microbiology and Infection 2022;28(3):410-418
33. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discovery Today 2003;8(20):934-943
34. Iavarone C, O’hagan DT, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Review of Vaccines 2017;16(9):871-881
35. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human Vaccines & Immunotherapeutics 2015;11(2):477-488
36. Ariamanesh M, Porouhan P, PeyroShabany B, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Investigation 2022;40(1):26-34
37. Petrović V, Vuković V, Patić A, et al. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—A comparative study from Novi Sad, Serbia. 2022;17(2):e0263468
| Issue | Vol 5, No 3 (2022); in press | |
| Section | Original Article | |
| Keywords | ||
| COVID-19 Vaccines Hemodialysis Neutralizing antibody SARS-CoV-2 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
